Incyte Corp. (INCY)
113.07
-0.20
(-0.18%)
USD |
NASDAQ |
Oct 16, 16:00
112.05
-1.02
(-0.90%)
After-Hours: 20:00
Incyte Cash from Investing (Quarterly) : -51.79M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -51.79M |
| March 31, 2026 | -88.20M |
| December 31, 2025 | -37.42M |
| September 30, 2025 | -47.42M |
| June 30, 2025 | -18.87M |
| March 31, 2025 | 1.097M |
| December 31, 2024 | -21.46M |
| September 30, 2024 | 38.27M |
| June 30, 2024 | 213.82M |
| March 31, 2024 | -73.11M |
| December 31, 2023 | -154.50M |
| September 30, 2023 | -17.19M |
| June 30, 2023 | -7.429M |
| March 31, 2023 | -28.56M |
| December 31, 2022 | -20.91M |
| September 30, 2022 | -28.40M |
| June 30, 2022 | -12.48M |
| March 31, 2022 | -16.75M |
| December 31, 2021 | -66.05M |
| September 30, 2021 | -32.75M |
| June 30, 2021 | -49.14M |
| March 31, 2021 | -59.75M |
| December 31, 2020 | -102.73M |
| September 30, 2020 | -14.45M |
| June 30, 2020 | -43.26M |
| Date | Value |
|---|---|
| March 31, 2020 | -108.56M |
| December 31, 2019 | -30.03M |
| September 30, 2019 | 12.28M |
| June 30, 2019 | -45.15M |
| March 31, 2019 | -24.56M |
| December 31, 2018 | -36.10M |
| September 30, 2018 | -17.88M |
| June 30, 2018 | -3.922M |
| March 31, 2018 | -28.53M |
| December 31, 2017 | -143.00M |
| September 30, 2017 | -30.84M |
| June 30, 2017 | -37.32M |
| March 31, 2017 | -138.82M |
| December 31, 2016 | -36.01M |
| September 30, 2016 | -9.952M |
| June 30, 2016 | -215.28M |
| March 31, 2016 | 28.76M |
| December 31, 2015 | -4.529M |
| September 30, 2015 | -15.22M |
| June 30, 2015 | -26.69M |
| March 31, 2015 | -58.58M |
| December 31, 2014 | -3.518M |
| September 30, 2014 | -58.69M |
| June 30, 2014 | -28.54M |
| March 31, 2014 | -47.69M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | -159.99M |
| Regeneron Pharmaceuticals, Inc. | -92.70M |
| AbbVie, Inc. | -1.197B |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Biogen, Inc. | -3.839B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 507.66M |
| Cash from Financing (Quarterly) | 65.46M |
| Free Cash Flow | 1.890B |
| Free Cash Flow Per Share (Quarterly) | 2.378 |
| Free Cash Flow to Equity (Quarterly) | 496.41M |
| Free Cash Flow to Firm (Quarterly) | 495.70M |
| Free Cash Flow Yield | 8.14% |